A long-acting form of Bayer’s blood pressure drug Adalat prevents heart attacks and strokes in angina patients and cuts the need for operations to treat blood vessel blockages, a study showed on Sunday. Adalat was Bayer’s second-biggest drug last year with sales of $817 million and is key for the German pharmaceuticals and chemicals group, which has few big-selling medicines and a poor research pipeline. Details of the study, involving more than 7,600 patients and released at the annual congress of the European Society of Cardiology, showed that nifedipine, or Adalat, was safe for patients on other drugs for stable angina.
